Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27950
Title: A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
Austin Authors: Wu, Yi-Long;Tsuboi, Masahiro;John, Thomas ;Grohe, Christian;Majem, Margarita;Goldman, Jonathan W;Laktionov, Konstantin;Kim, Sang-We;Kato, Terufumi;Vu, Huu-Vinh;Lu, Shun;Lee, Kye-Young;Akewanlop, Charuwan;Yu, Chong-Jen;de Marinis, Filippo;Bonanno, Laura;Domine, Manuel;Shepherd, Frances A;Zeng, Lingmin;Hodge, Rachel;Atasoy, Ajlan;Rukazenkov, Yuri;Herbst, Roy S
Affiliation: Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain..
Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA
Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin, Germany
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China..
Medical Oncology
Late Oncology Statistics, AstraZeneca, Cambridge, UK
Late Oncology Research & Development, AstraZeneca, Cambridge, UK
David Geffen School of Medicine at University of California Los Angeles, CA, USA
Late Oncology Statistics, AstraZeneca, Gaithersburg, MD, USA
Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow, Russia
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Department of Thoracic Surgery, Choray Hospital, Ho Chi Minh City, Vietnam
Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
Precision Medicine, Lung Cancer Center, Konkuk University Medical Center, Seoul, South Korea
Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand
Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch and National Taiwan University College of Medicine, Taipei, Taiwan
Thoracic Oncology Division, European Institute of Oncology (IEO), IRCCS, Milan, Italy
Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy
Instituto de Investigacion Sanitaria-Fundacion de la Jimenez Diaz, Madrid, Spain
Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada
Issue Date: 1-Dec-2021
Date: 2021-11-01
Publication information: Future Oncology 2021; 17(35): 4827-4835
Abstract: Here, we summarize the initial results from the ADAURA clinical study looking at treatment with osimertinib in patients with a specific type of non-small cell lung cancer (also called NSCLC). Osimertinib (TAGRISSO┬«) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. EGFR stands for 'epidermal growth factor receptor'. It is a protein present on the surface of both healthy and cancer cells that can regulate how cells grow and divide. Sometimes, certain mutations in EGFR can result in the EGFR protein malfunctioning, which can lead to the formation of cancer, like EGFR-mutated NSCLC. Based on previous clinical studies, osimertinib is already approved for use in patients with EGFR-mutated NSCLC that has spread beyond the lung (metastatic disease). This medication works to stop, prevent, or slow the growth of EGFR-mutated NSCLC tumors, by specifically blocking the activity of EGFR. In the ADAURA clinical study, participants had resectable EGFR-mutated NSCLC, which means they had tumors that can be removed by surgery. Participants took either osimertinib or a placebo (a dummy drug with no active ingredient) after having their tumors removed by surgery. Post-surgery chemotherapy was allowed, but not compulsory (this was decided by the participant and their doctor). To date, the study has shown that osimertinib could be beneficial for patients with resectable EGFR-mutated NSCLC. Participants who took osimertinib have stayed cancer-free for longer than those who took the placebo, regardless of whether or not they received chemotherapy after surgery. Osimertinib treatment also reduced the risk of tumors spreading to the brain and spinal cord, otherwise known as the central nervous system (also called CNS). The side effects experienced by the participants taking osimertinib have been consistent with what we already know. Based on the results from ADAURA, osimertinib has been approved for the treatment of resectable EGFR-mutated NSCLC after tumor removal. The ADAURA study is still ongoing and more results are expected to be released in the future. ClinicalTrials.gov NCT number: NCT02511106.
URI: https://ahro.austin.org.au/austinjspui/handle/1/27950
DOI: 10.2217/fon-2021-0752
Journal: Future Oncology
PubMed URL: 34723634
Type: Journal Article
Subjects: CNS metastases
Chemotherapy
EGFR gene mutation
Lay summary
Non-small cell lung cancer
Osimertinib
Plain language summary
Surgery
Appears in Collections:Journal articles

Show full item record

Page view(s)

14
checked on Apr 12, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.